CTNM · Contineum Therapeutics, Inc.
$17.13
+1.11 (+6.93%)
At close · Aug 21
Market Cap
$602.69M
Shares
37.62M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$16.02
Open$15.80
Day$15.68–16.29
52W close$8.87–16.39
Avg vol 30d410K
Short int2.8M · 7.5% float · 13.5d
Short vol67%
Last earningsOct 30, 2025
DataApr 2024–Aug 2026
Filing10-Q · Jul 30
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 30, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+22%
above
Price vs 50-day avg
+12%
above
RSI (14)
60
neutral
MACD trend
Positive
52-week position
95%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+11%
trailing
6-month return
+4%
trailing
YTD return
+40%
this year
Relative strength
−7%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $14 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
+12% holders QoQ · +28 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.50% of float · ▲ +15.5% MoM · 13.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
101 holders — near 2-yr high, broad support
Squeeze score
89
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+0%
Y/Y
Free cash flow
$-55.5M
Balance sheet
$75.6M
net cash
Quant / Vol
risk profile
Volatility
69%
annualized · 1-yr
Max drawdown
−30%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+22%
Bullish
Price vs 50-day avg
+12%
Bullish
RSI (14)
60
Neutral
MACD trend
Positive
Bullish
52-week position
95%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $14 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
+12% holders QoQ · +28 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.50% of float · ▲ +15.5% MoM · 13.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
101 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $9
Now $16 · 95%
Range high $16
vs 200-day avg +22%
vs 50-day avg +12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTNM
this stock
Contineum Therapeutics, Inc.
|
$602.69M | +40.2% | -100.0% | — | 7.5% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTNM | +4.7% | +11.5% | +4.4% | +3.4% | +40.2% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +6.7% | +8.2% | -6.7% | +1.3% | +28.3% |
Key facts
CIK
1855175
CUSIP
21217B100
13F (30d)
101 filings
99 filers
Visit website
Investor relations